Is It a New Era of Anti-bribery Enforcement in China?
DOI:
https://doi.org/10.5278/ojs.njcl.v0i2.2669Abstract
Bribery harms the global playing field as it distorts fair completion, undermines honest practices and increases transactional costs, which results in significant uncertainty in transnational business. The Chinese Ministry of Public Security (MPS)’ crackdown on the pharmaceutical company GlaxoSmithKline (GSK)’s bribery and corruption, signals a broad trend toward elevated scrutiny of all foreign corporations operating in China. The case of GSK serves as a timely wake-up call indicating that China’s anti-bribery law has shown its teeth against foreign multinational companies (MNCs). GSK’s bribery may also invoke anticorruption enforcement across multiple major jurisdictions including both the U.S. and UK, as well as, China. The more global approach of enforcement agencies should incentivise greatly MNCs to design and implement anti-bribery compliance programmes commensurate with their risk of corruption, with a particular regard to China’s unique business and legal culture.
Downloads
Published
Issue
Section
License
NJCL issues as of 2017 are licensed under the CC BY 4.0 license. Authors retain copyright to their work but grant the journal the right of first publication. All rights are reserved for issues from 2003 until 2016.